<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jacobson, Anne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Boden, William E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">AIM-HIGH: Niacin Provides No Added Benefit for Statin Users with Well-Controlled LDL</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-17</style></pages><abstract><style  face="normal" font="default" size="100%">Add-on therapy with high-dose extended-release niacin provides no additional reduction in cardiovascular events in patients with dyslipidemia and a history of cardiovascular disease who are treated to target low-density lipoprotein levels with a statin, according to findings from a randomized trial.</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>